Therefore, and in spite of displaying proapoptotic functions, p38 may constitute a target for prostate cancer treatment given its demonstrated contribution to some prostate cancer hallmarks, as androgen dependence and metastatic phenotype acquisition. Here, MAPK1 is linked to prostate carcinoma.